10.26
+0.26(+2.60%)
Currency In USD
| Previous Close | 10 |
| Open | 10 |
| Day High | 10.31 |
| Day Low | 9.83 |
| 52-Week High | 13.33 |
| 52-Week Low | 5.68 |
| Volume | 302,409 |
| Average Volume | 1.29M |
| Market Cap | 606.12M |
| PE | -3.09 |
| EPS | -3.32 |
| Moving Average 50 Days | 9.36 |
| Moving Average 200 Days | 8.11 |
| Change | 0.26 |
If you invested $1000 in Cullinan Therapeutics, Inc. (CGEM) since IPO date, it would be worth $343.03 as of December 25, 2025 at a share price of $10.26. Whereas If you bought $1000 worth of Cullinan Therapeutics, Inc. (CGEM) shares 3 years ago, it would be worth $1,055.56 as of December 25, 2025 at a share price of $10.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
GlobeNewswire Inc.
Dec 08, 2025 3:31 PM GMT
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, I
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management t